# OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

> **NCT00130403** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 290 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** risedronate sodium

## Key facts

- **NCT ID:** NCT00130403
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2011-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130403, "OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00130403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*